Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients

  • Intercept Pharmaceuticals Inc ICPT has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free survival in patients with primary biliary cholangitis (PBC).
  • In the analysis, 209 patients treated with OCA in the POISE long-term safety extension study had significantly greater transplant-free survival than patients in the external control groups. 
  • In the OCA arm, three events were observed versus 146 and 276 occurrences in the Global PBC and UK-PBC external control cohorts, respectively. 
  • The hazard ratio favoring OCA was 0.20 in Global PBC and 0.28 in UK-PBC in a weighted analysis. 
  • Thus, patients treated with OCA had a 72% to 80% lower risk of death or liver transplant than the control groups at any time during follow-up. 
  • Price Action: ICPT shares are down 0.68% at $18.91 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsprimary biliary cholangitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!